ARPA-H's Serious Mental Illness Special Notice Is Now Open — An August 9 Solution-Summary Deadline, A $139M Program Behind It, And $50M To Match State Psychedelic Research

ARPA-H does not run its solicitations the way NIH does, and the difference matters enormously for anyone trying to win its money. There is no standing R01-style application, no study section, no three-times-a-year cycle. Instead, the agency posts Special Notices and Innovative Solutions Openings (ISOs) that invite a short solution summary first — and only the summaries that clear that first gate are asked for a full proposal. On the funding table right now is one of the most policy-charged solicitations the agency has issued: Special Notice SN-26-156, "Accelerating Medical Treatments for Serious Mental Illness," with solution summaries due August 9, 2026, submitted through the Proactive Health Office ISO (ARPA-H-SOL-24-106).

For research teams, biotech startups, academic medical centers, and clinical networks working on serious mental illness — schizophrenia, bipolar disorder, treatment-resistant depression, severe PTSD — this is a live opportunity with a two-week runway from today. But the Special Notice is only the visible tip. Behind it sits the $139.4 million EVIDENT initiative and a specific commitment to put at least $50 million toward matching state government investments in psychedelic research for populations with serious mental illness. Understanding that structure is what separates a solution summary that lands from one that misreads the moment. This is the deep dive on the mechanism, the money, and the strategy.

What EVIDENT is, and why SN-26-156 exists

EVIDENT — Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health — is ARPA-H's behavioral-health flagship, funding up to $139.4 million to spur new, more precise, and more effective therapies for behavioral-health conditions. The program's animating premise is the one ARPA-H applies across its portfolio: the science bottleneck in serious mental illness is not a shortage of promising ideas, it is the absence of rigorous, rapid, real-world validation. Too many candidate therapies — including novel pharmacology, neurotechnology, digital interventions, and psychedelic-assisted approaches — die in the long, underpowered gap between an encouraging early signal and a definitive clinical answer. EVIDENT is built to compress that gap.

SN-26-156 is the specific solicitation channel through which ARPA-H is soliciting solutions under this banner, and it is explicitly tied to the Executive Order to Accelerate Medical Treatments for Serious Mental Illness. That EO is the reason a portion of EVIDENT — at least $50 million — is earmarked to match state investments in psychedelic research for serious mental illness. This is an unusual and strategically important structure. ARPA-H is not simply funding research; it is offering to amplify state dollars, which means the most competitive responses may be those that arrive with a state partner already at the table. We covered the policy origins of this push in our earlier analysis of the Trump psychedelic executive order and ARPA-H's EVIDENT initiative; this piece is about the open solicitation and how to respond to it.

The solution-summary gate — ARPA-H's real filter

The single most misunderstood feature of ARPA-H funding is the solution summary. It is a short document — typically a handful of pages plus a slide or two — that describes the problem, the proposed solution, why it is a leap beyond the current state of the art, the technical approach, the metrics of success, the team, and a rough cost and schedule. It is not a full proposal. ARPA-H program managers read solution summaries and respond with an invitation to submit a full proposal, a request for more information, or a decline.

This front gate has two consequences for applicants working toward the August 9 deadline. First, the binding constraint is not full-proposal preparation time — it is the quality and clarity of the summary. A team that can articulate, in five pages, a specific measurable leap over the current standard of care for a defined SMI population is in far better shape than a team with deep preliminary data but a diffuse pitch. Second, ARPA-H rewards ambition framed as milestones. The agency's DARPA-derived culture wants a "heilmeier catechism" answer: what are you trying to do, why is it hard, why will your approach succeed where others failed, and how will you know — with quantified go/no-go metrics — whether it is working. A summary that reads like an incremental NIH aim will not survive; one that promises a definable breakthrough with a credible validation plan will.

Who should be responding — and how the state-match angle changes eligibility calculus

ARPA-H's ISOs are broadly open. Solicitations under the Mission Office ISOs generally accept proposals from a wide range of performers — universities, nonprofit research institutions, for-profit companies including small businesses, and teams that combine them. There is no requirement to be a traditional NIH-funded lab; in fact, ARPA-H actively seeks nontraditional performers, including biotech startups and clinical-technology companies that would never fare well in a conventional study-section review.

The $50 million state-match provision reshapes who has an edge. Because that money is designed to match state government investments in psychedelic research for serious mental illness, the applicants best positioned to capture it are those who can bring a state partner and its dollars to the table — a state behavioral-health agency, a state-funded university clinical program, or a state psychedelic-research initiative already standing up under recent state legislation. A research team that has quietly secured a state commitment to co-invest is offering ARPA-H exactly the leverage the EO asked for. Teams without that relationship can still respond to the broader SN-26-156 and EVIDENT opportunity — the $50M match is a subset of the $139.4M program — but they should understand that the psychedelic-and-state-match lane is where a distinct competitive advantage exists, and act accordingly if they can.

The compressed calendar and the ARPA-H review reality

The immediate operational fact is the August 9, 2026 solution-summary deadline, submitted through the Proactive Health Office ISO (ARPA-H-SOL-24-106). That leaves a short window to produce a crisp summary, assemble the right team, and — for teams pursuing the match lane — confirm a state partner. ARPA-H's process moves faster than NIH's after that gate: invited teams are asked for full proposals and, if selected, negotiated into awards (often Other Transaction agreements or contracts rather than grants), which changes the intellectual-property and reporting posture relative to a standard federal grant. Applicants should be prepared for an outcome-driven, milestone-funded relationship with an engaged program manager, not the hands-off administration of a research grant.

Because the review is program-manager-driven, direct engagement is legitimate and expected. ARPA-H encourages prospective performers to read the solicitation on SAM.gov carefully and, where the process allows, to seek clarity through the official channels before submitting. Teams that tailor their summary to the specific technical thrust and metrics the program manager has signaled — rather than submitting a generic mental-health research pitch — consistently fare better.

Why this solicitation matters beyond the deadline

Serious mental illness has been one of the most persistent failures of the American biomedical enterprise. The pharmacological toolkit for schizophrenia and bipolar disorder is decades old in its mechanisms; treatment-resistant depression and severe PTSD leave large populations without effective options. ARPA-H's bet — validated, rapid, real-world therapeutic development, with an explicit willingness to fund novel modalities including psychedelics and to leverage state co-investment — is a structural departure from how mental-health research has been funded for a generation.

For the field, SN-26-156 and the EVIDENT initiative behind it represent a rare alignment of money, mandate, and mechanism: $139.4 million, an executive order pushing for speed, a $50 million lever to multiply state dollars, and an agency built to move faster than the incumbent system. For any team with a credible, ambitious, measurable approach to serious mental illness, the first step is small and the clock is short — a solution summary, due August 9. The teams that treat that short document with the seriousness of a full proposal, and that arrive with a state partner where they can, are the ones most likely to be invited to the table.